106 results
Page 2 of 6
6-K
EX-99.4
9nru n4xo
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.2
18tw aplyx2hk21n2l0
10 Aug 23
Current report (foreign)
8:28am
6-K
tfc ki2zx3df734k
5 Jun 23
Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
9:20am
6-K
EX-99.1
e5w8ds2kknlchf4
5 Jun 23
Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
9:20am
6-K
EX-99.3
2hhuh7xv64rfg5x8t8r
10 May 23
Current report (foreign)
7:27am
6-K
3mxqvrs7d20k1
18 Apr 23
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival
4:15pm
6-K
EX-99.1
jb8 vabu83vc78ktr
18 Apr 23
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival
4:15pm
6-K
zf97 j1kxoixqhve4xtl
8 Dec 22
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
4:59pm
6-K
EX-99.1
fr6mg1r6e9h0la5c
8 Dec 22
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
4:59pm
6-K
EX-99.1
tuonaxnshmk60qz
2 Dec 22
Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors
5:08pm
6-K
w731fh8avxyx5j70
14 Nov 22
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting
7:59am
6-K
EX-99.1
qu1 uvnhzs4q
14 Nov 22
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting
7:59am
6-K
EX-99.4
3741 czpphxsq9y6p
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
6-K
EX-99.3
wz6yt4
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
424B7
xt2kck4
30 Sep 22
Prospectus with selling stockholder info
4:15pm
6-K
EX-1.1
sfad55i 7v5czp
9 Sep 22
Cautionary Note Regarding Forward Looking Statements
4:29pm
424B5
jo576xxxgw69i43n pc3
9 Sep 22
Prospectus supplement for primary offering
4:23pm
6-K
EX-99.1
yx3 mh3jcszypqmw06
9 Sep 22
Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress
12:33pm
6-K
EX-99.2
gmtgf8
9 Sep 22
Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress
12:33pm
6-K
EX-99.2
xrcfr
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am